MDACC Study No:2005-0726 ( NCT No: NCT00475020)
Title:Allogeneic stem cell transplantation for myelofibrosis and myelodysplastic syndrome using reduced intensity busulfan and fludarabine conditioning.
Principal Investigator:Uday Popat
Treatment Agent:Busulfan; Fludarabine; Thymoglobulin
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if using a combination of
fludarabine, busulfan, and antithymocyte globulin (ATG) can help to control
myelofibrosis or myelodysplastic syndrome in patients receiving a bone marrow
or blood stem cell transplant. The safety of these drugs will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Blood And Marrow Transplantation; Hematologic Disorder; Leukemia
Phase of Study:Phase II
Treatment Agents:Busulfan
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Four weeks
Supported By:N/A
Return Visit:Patients are followed continuously at MDACC until 100 days post transplant then
q 3 mo for one year and q 6 months for second year after transplant and
annually thereafter
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Uday Popat
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-745-3055
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults